NVDA vs. REGN
NVDA (NVIDIA Corporation) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. NVDA operates in Semiconductors (Technology), while REGN operates in Biotechnology (Healthcare). Over the past 10 years, NVDA returned 68.47%/yr vs 5.18%/yr for REGN. At a 0.28 correlation, their price movements are largely independent.
Performance
NVDA vs. REGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVDA achieves a 12.01% return, which is significantly higher than REGN's -20.58% return. Over the past 10 years, NVDA has outperformed REGN with an annualized return of 68.47%, while REGN has yielded a comparatively lower 5.18% annualized return.
NVDA
- 1D
- 1.73%
- 1M
- -2.94%
- YTD
- 12.01%
- 6M
- 12.58%
- 1Y
- 47.43%
- 3Y*
- 75.35%
- 5Y*
- 64.54%
- 10Y*
- 68.47%
REGN
- 1D
- -3.79%
- 1M
- -14.36%
- YTD
- -20.58%
- 6M
- -12.84%
- 1Y
- 24.63%
- 3Y*
- -6.19%
- 5Y*
- 3.39%
- 10Y*
- 5.18%
NVDA vs. REGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVDA NVIDIA Corporation | 12.01% | 38.92% | 171.25% | 239.02% | -50.26% | 125.48% | 122.30% | 76.94% | -30.82% | 81.99% |
REGN Regeneron Pharmaceuticals, Inc. | -20.58% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
Correlation
The correlation between NVDA and REGN is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 25, 1999 | 0.28 |
Over the past year, the correlation between NVDA and REGN has dropped to 0.00 - well below their long-term average of 0.28, suggesting their price drivers have been diverging.
Fundamentals
NVDA:
$5.09T
REGN:
$65.84B
NVDA:
$6.53
REGN:
$41.05
NVDA:
31.97
REGN:
14.89
NVDA:
20.13
REGN:
4.42
NVDA:
26.03
REGN:
2.10
NVDA:
$253.49B
REGN:
$14.92B
NVDA:
$187.95B
REGN:
$12.61B
NVDA:
$192.76B
REGN:
$5.74B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVDA vs. REGN — Risk / Return Rank
NVDA
REGN
NVDA vs. REGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NVIDIA Corporation (NVDA) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVDA | REGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.62 | ||
| Sortino ratioReturn per unit of downside risk | +0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.16 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 2.36 | 0.96 | +1.40 |
| Martin ratioReturn relative to average drawdown | 5.73 | 3.20 | +2.54 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NVDA | REGN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.37 | 0.75 | +0.62 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.25 | 0.11 | +1.14 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 1.38 | 0.16 | +1.22 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.63 | 0.16 | +0.47 |
Drawdowns
NVDA vs. REGN - Drawdown Comparison
The maximum NVDA drawdown since its inception was -89.72%, roughly equal to the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for NVDA and REGN.
Loading charts...
Drawdown Indicators
| NVDA | REGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.72% | -91.81% | +2.09% |
Max Drawdown (1Y)Largest decline over 1 year | -20.21% | -25.85% | +5.64% |
Max Drawdown (3Y)Largest decline over 3 years | -36.88% | -59.69% | +22.81% |
Max Drawdown (5Y)Largest decline over 5 years | -66.34% | -59.69% | -6.65% |
Max Drawdown (10Y)Largest decline over 10 years | -66.34% | -59.69% | -6.65% |
Current DrawdownCurrent decline from peak | -11.39% | -48.71% | +37.32% |
Average DrawdownAverage peak-to-trough decline | -36.20% | -42.39% | +6.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.30% | 7.73% | +0.57% |
Volatility
NVDA vs. REGN - Volatility Comparison
NVIDIA Corporation (NVDA) and Regeneron Pharmaceuticals, Inc. (REGN) have volatilities of 13.14% and 12.61%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVDA | REGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.14% | 12.61% | +0.53% |
Volatility (6M)Calculated over the trailing 6-month period | 26.37% | 22.61% | +3.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.81% | 33.09% | +1.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 51.75% | 30.82% | +20.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.85% | 32.18% | +17.67% |
Dividends
NVDA vs. REGN - Dividend Comparison
NVDA's dividend yield for the trailing twelve months is around 0.14%, less than REGN's 0.60% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVDA NVIDIA Corporation | 0.14% | 0.02% | 0.03% | 0.03% | 0.11% | 0.05% | 0.12% | 0.27% | 0.46% | 0.29% | 0.45% | 1.20% |
REGN Regeneron Pharmaceuticals, Inc. | 0.60% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NVDA vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between NVIDIA Corporation and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVDA vs. REGN - Profitability Comparison
NVDA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a gross profit of 61.16B and revenue of 81.62B. Therefore, the gross margin over that period was 74.9%.
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.
NVDA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported an operating income of 53.54B and revenue of 81.62B, resulting in an operating margin of 65.6%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.
NVDA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a net income of 58.32B and revenue of 81.62B, resulting in a net margin of 71.5%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.
Frequently Asked Questions
NVDA and REGN have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVDA has higher volatility (13.14%) compared to REGN (12.61%). In terms of maximum drawdown, NVDA dropped -89.72% vs REGN's -91.81%.
NVDA currently has the higher Sharpe Ratio (1.37 vs 0.75), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVDA and REGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer